Search Results
Results found for "Chris Evans"
- Bell-Evans model and steered molecular dynamics in uncovering the dissociation kinetics of ligands..
October 2022 Bell-Evans model and steered molecular dynamics in uncovering the dissociation kinetics optimized approach of combining the data derived from steered molecular dynamics simulations and the Bell-Evans
- Why Sokhom Pin Never Left GPCRs, Even When Everyone Else Did
But Sokhom Pin stayed loyal to GPCRs , even when big pharma turned its gaze to other targets like kinases
- The Imprecision Problem: Why Your GPCR Drug Discovery Program Is Off-Track Before It Even Starts
But hereâs the reality: even ultra-specialized experts canât fix systemic dysfunction in their spare Even flawless experiments collapse under sloppy systems. data management  pipeline, teams waste hours cleaning, reconciling, and integrating before they can even
- GPCR Drug Discovery Summit 2026: What to Expect in Boston â and How to Register
Chris Dockendorff is the founder of Function Therapeutics, a small biotech on the University of WisconsinâMilwaukee At the 5th GPCRs Targeted Drug Discovery Summit, Chris is leading a roundtable on biased signaling, endosomal
- Embark on a GPCR Adventure: Your Weekly Research Expedition! | Oct 21-27, 2024
Dimerization: Unveiling Its Role in Receptor Function and Signaling Sonja Peter , Brian Bender , Chris
- Sosei Heptares Confirms Senior Leadership Changes to Drive the Company Through the Next Stage ...
Chris Cargill appointed as President and Chief Executive Officer ⢠Dr.
- Embark on a GPCR Adventure: Your Weekly Research Expedition! | Oct 21-27, 2024
Dimerization: Unveiling Its Role in Receptor Function and Signaling Sonja Peter , Brian Bender , Chris
- đ° GPCR Weekly News, October 9 to 15, 2023
success Sosei and PharmEnable extend neurological disease drugs hunt Sosei Heptaresâ President & CEO Chris
- đ° GPCR Weekly News
INV-202, an Oral, Peripherally-acting CB1 Inverse Agonist, in Patients with Diabetic Kidney Disease Chris
- đ° GPCR Weekly News, October 16 to 22, 2023
Topline Safety and Tolerability Data from Proof-of-Concept Studies Sosei Heptaresâ President & CEO Chris
- đ° GPCR Weekly News, February 13 to 19, 2023
From the scientistâs view: a conversation with ⌠Chris Tate AI is dreaming up drugs that no one has ever
- Unlocking the Future of Medicine: Advancements in GPCR Research
This week's highlight includes congrats to Omolade Otun, Chris de Graaf, Cherine Bechara, et al. for
- Targeting GPCRs in the CNS: Advances in Drug Discovery Strategies
Source: Kim J, Choi C. 2018 Feb;98:222-232. doi: 10.1016/j.biopha.2017.12.056 Azam S, Haque ME, Jakaria M, Jo SH, Kim IS, Choi Cells. 2020 Feb 23;9(2):506. doi: 10.3390/cells9020506 Â Kim J, Choi C.
- Biased Agonism at the GLP-1 Receptor: A Pathway to Improved Therapeutic Outcomes
Cary, B.P., et al., New Insights into the Structure and Function of Class B1 GPCRs. Â
- Nanobodies: New Dimensions in GPCR Signaling Research
G., Choi, H. J., Fung, J. J., Pardon, E., Casarosa, P., Chae, P. S., Devree, B. T., Rosenbaum, D.
- GPCR Happy Hour Boston 2026 â April 29 | Dr. GPCR Community Event
GPCR community is gathering in Boston for an informal evening of real conversation. The evening takes place at Pressed Cafe, 105 Huntington Ave â steps from The Colonnade, where the 5th It's a gathering of people who already share something (a deep commitment to GPCR science) even if they're Who's making the GPCR Happy Hour evening possible GPCR Happy Hour is made possible by four companies Who should come This evening is open to pharma, biotech, academia, and students.
- From Student to Mentor: What Alessandro Nicoli Learned About Leading in Science
Antonella Di Pizioâs lab , there was almost nothingâno team, no culture, not even proper desks. responsibilities: from building computational models of GPCRs to guiding interns, masterâs students, and even âI remember my first dayâwe were even sharing the desk.
- Fentanyl and Xylazine: Why Breathing Fails in Overdose
The combination is not merely additive; itâs synergistic, shrinking tidal volume even when breathing the two drugs, there was a potentiation of fentanylâs effect on tidal volumeâmice were bringing in even Even if the respiratory rate doesnât appear drastically lower, those pauses send oxygen levels plummeting A patient might appear stable on an oxygen monitor, even as their breathing mechanics are deteriorating Catherineâs work matters: it shows in mechanistic detail how fentanyl and xylazine change what overdose even
- The Boston Happy Hour: What Happens When GPCR Scientists Enter the Cafe
Conversations started around the name tag table before anyone had even found their drink. At some point during the evening, I noticed a family at a nearby table checking out our check-in table Even the room around us caught the energy. This was the result.
- The Perils and Guardrails of Modifying Signalling Proteins in Bioassays
small molecules, lipids, receptor-activity modifying proteins, autoantibodies, membrane stretch, and even the strongest coupling partner GÎąs (Figure 2A), and for the glucagon-like-peptide-1 receptor (GLP-1R) even van der Westhuizen ET, Valant C, Sexton PM, Christopoulos A. Manchanda Y, ElEid L, Oqua AI, Ramchunder Z, Choi J, Shchepinova MM, et al. Why even physicists still don't understand quantum theory 100 years on.
- Why Biotech Fundraising Fails Due to Intellectual Property Gaps
. đ Many biotech fundraising efforts stall even with solid science and data. When it is fragmented, even promising science struggles to move the round forward. Even experienced founders underestimate how sensitive investors are to ownership details. That uncertainty increases perceived risk, even if the underlying science is compelling. Even if the risk is manageable, not addressing it makes the fundraising process harder.
- Drug Discovery Pharmacology Principles That Turn Assays Into Real Medicines
When responses are scaled consistently, comparisons remain meaningful even if the absolute maximum is Even experienced biologists sometimes treat ECâ â as if it reflects ligand affinity. Kenakin reveals how scaled pharmacological metrics allow teams to interpret receptor signaling changes even Even potent inhibitors may fail simply because they never reach sufficient concentration in vivo . Even promising molecules collapse due to safety issues, pharmacokinetics, or unexpected biology.
- The Hidden Cost of Unclear Biotech Positioning
Business development conversations feel inconsistent, even when the company and the science have not Over time, this constant adjustment drains confidence and momentum, even when the science is strong. The same company sounds different depending on the meeting , even when the science and the strategy have instead of the core value 5ď¸âŁ The CEO and scientific leadership describe the company differently , even Even rejection becomes useful, because it is based on clear criteria rather than confusion. â A biotech
- From GPCR Data Chaos to Decisive Action
Is Your GPCR Program Slowing DownâEven With Good Data? Youâre not alone. I call it the Lego Bucket Problem : Youâve got CRO output, internal assay data, maybe even some promising calendly.com/drgpcr/yamina-corner Or explore how we can work together: đ Yamina.org đ Key Takeaways â Even
- Misread the Curve, Misjudge the Drug: Rethinking Antagonism in GPCR Pharmacology
But if the antagonist binds tightly and dissociates slowly, the receptor remains blocked, even at high This mimics non-competitive behavior, even if the antagonist occupies the orthosteric site. Antagonist âhogsâ the receptor, depressing the response, even if more agonist is added.
- Innovative Data-Driven Solutions: The pHSense Revolution
Even minor adjustments can compromise photophysical properties. constructed the platform, tested every variableâpKa, brightness, lifetimeâand made decisions that few would even The assay is compatible with SNAP-tags, FLAG-tags, HA-tags, and even antibody fragments for native GPCRs
- Is Your Agonist Really âWorkingââOr Are You Just Seeing What Your System Allows?
Through powerful analogies (think batteries and balance scales), Terry reveals why different tissuesâand even
- Why Fundraising Mistakes Kill Strong Biotech Startups
. đ None of these moves looks fatal on their own, yet together they quietly weaken even strong biotech And under pressure, even strong teams begin to confuse movement with direction. đ In early-stage biotech Roles are added to demonstrate scale, even when the organization is not structurally ready to support Strategy continues to shape decisions even when external pressure rises. â This is the point where biotech When fundraising leads and strategy reacts, even strong biotech startups slowly lose coherence. â The
- How Early Strategic Decision Making Creates Alignment and Better Results
. đ In biotech, where cycles are long and feedback is slow, this gap becomes even more pronounced. Early decisions shape what the team optimizes for , even when no one explicitly states it. 3ď¸âŁ What will where alignment becomes the invisible mechanism that turns intent into movement. đ Without alignment, even Over time, this friction compounds and erodes confidence, even when the underlying strategy is sound.
- From Lab Logic to Leadership: How Scientific Thinking Holds Back Biotech Operations
. đ Most founders donât even realize theyâre still running their company like an academic research group Startups demand something different: â  Clarity of direction even when the picture is incomplete. The transition between the two isnât automatic, even for the most capable founders.






















